Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 18/20 | 0.70 |
| ▸ | MTNR1B | P49286 | 18/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299350 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BESR1MAPTMAPK10 | |
| SCHEMBL11932345 | 0.79 | MTNR1A (0.60) | MTNR1AMTNR1BKDM4EALDH1A1 | |
| SCHEMBL12215345 | 0.78 | MTNR1A (0.59) | MTNR1AMTNR1B | |
| SCHEMBL2297423 | 0.76 | MTNR1A (1.00) | MTNR1AMTNR1BESR1MAPTMAPK10 | |
| SCHEMBL2297427 | 0.76 | MTNR1A (1.00) | MTNR1AMTNR1BESR1MAPTMAPK10 | |
| SCHEMBL11931989 | 0.76 | MTNR1A (1.00) | MTNR1AMTNR1BESR1MAPTMAPK10 | |
| SCHEMBL2296602 | 0.74 | MTNR1A (0.56) | MTNR1AMTNR1B | |
| SCHEMBL2297410 | 0.74 | MTNR1A (0.65) | MTNR1AMTNR1B | |
| SCHEMBL2297408 | 0.74 | MTNR1A (0.65) | MTNR1AMTNR1B | |
| SCHEMBL2297648 | 0.73 | MTNR1A (0.53) | MTNR1AMTNR1BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349879-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8318784-B2 | — | — | 2012-11-27 | — | — | US | disclosed |
| US-20110196003-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196003-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, CYP11B2 | MTNR1A 1/4885MTNR1B 2/4885KDM4E 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.